Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study

Diabetes, Obesity and Metabolism

Volumn 18, Issue 8, 2016, Pages 840-843

  Rathmann, W ^a   Bongaerts, B ^a   Kostev, K ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b IQVIA   (United States)

Author keywords

glucose lowering drugs; glycaemic control; HbA1c; metformin; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSE REDUCTASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; AGED; AGONISTS; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; METABOLISM; MIDDLE AGED; ODDS RATIO; PRIMARY HEALTH CARE;

AGED; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; MALE; METFORMIN; MIDDLE AGED; ODDS RATIO; PRIMARY HEALTH CARE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84969926507     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12673     Document Type: Article

References (15)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
2. Raebel MA, Ellis JL, Schroeder EB et al. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study. Pharmacoepidemiol Drug Saf 2014; 23: 699–710.
3. Thomsen RW, Baggesen LM, Søgaard M et al. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4734 people with type 2 diabetes. Diabetologia 2015; 58: 2247–2253.
4. Schunk M, Stark R, Reitmeir P, Rathmann W, Meisinger C, Holle R. Improvements in type 2 diabetes care? Pooled analysis of survey data in southern Germany (KORA) from 1999-2008. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2011; 54: 1187–1196.
5. Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009; 47: 617–626.
6. Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA 2014; 311: 2315–2325.
7. Ekström N, Miftaraj M, Svensson AM et al. Glucose-lowering treatment and clinical results in 163121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. Diabetes Obes Metab 2012; 14: 717–726.
8. Karter AJ, Moffet HH, Liu J et al. Glycemic response to newly initiated diabetes therapies. Am J Manag Care 2007; 13: 598–606.
9. Bennett WL, Maruthur NM, Singh S et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602–613.
10. Mathieu C, Barnett AH, Brath H et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract 2013; 67: 947–956.
11. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106–1118.
12. Du Y, Heidemann C, Schaffrath Rosario A et al. Changes in diabetes care indicators: findings from German National Health Interview and Examination Surveys 1997–1999 and 2008–2011. BMJ Open Diabetes Res Care 2015; 3: e000135.
13. Dinesh Shah A, Langenberg C, Rapsomaniki E et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1 · 9 million people. Lancet 2015; 385(Suppl. 1): S86.
14. Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 2015; 36: 2288–2296.
15. Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab 2014; 16: 977–983.